Literature DB >> 23834691

Multimarker approach for identifying and documenting mitigation of cardiovascular risk.

Marc S Penn1, Andrea B Klemes.   

Abstract

The widespread use of lipids to define risk has been a success based on the dramatic decrease in the incidence of transmural myocardial infarctions. This success and the fact that many patients with normal lipid levels go on to have acute coronary syndrome have led to investigations on the use of nonlipid-based inflammatory biomarkers to predict risk. Interestingly, as the physiology reflected by distinct biomarkers is better understood, there is increasing interest in multimarker approaches to determine risk and where a given patient may be on a spectrum of risk. In this perspective, we review data from over 95,000 patients who had a multimarker annual wellness panel to demonstrate the utility of multiple markers in defining those patients at risk. We discuss a novel multimarker panel for cardiovascular risk, define the differences between a multimarker approach and expensive amalgamations of multiple markers, and discuss how the field may develop in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23834691     DOI: 10.2217/fca.13.27

Source DB:  PubMed          Journal:  Future Cardiol        ISSN: 1479-6678


  3 in total

1.  Pentraxin 3, ficolin-2 and lectin pathway associated serine protease MASP-3 as early predictors of myocardial infarction - the HUNT2 study.

Authors:  Inga Thorsen Vengen; Tone Bull Enger; Vibeke Videm; Peter Garred
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

2.  Comprehensive biomarker testing of glycemia, insulin resistance, and beta cell function has greater sensitivity to detect diabetes risk than fasting glucose and HbA1c and is associated with improved glycemic control in clinical practice.

Authors:  Stephen A Varvel; Szilard Voros; Dawn L Thiselton; James V Pottala; Tara Dall; G Russell Warnick; Joseph P McConnell; Leila Ghaedi; Maciek Sasinowski; Timothy Graham
Journal:  J Cardiovasc Transl Res       Date:  2014-07-29       Impact factor: 4.132

3.  Knowledge of an inflammatory biomarker of cardiovascular risk leads to biomarker-based decreased risk in pre-diabetic and diabetic patients.

Authors:  Diego Alcivar-Franco; Scott Purvis; Marc S Penn; Andrea Klemes
Journal:  J Int Med Res       Date:  2018-01-31       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.